Cooper Companies (CH:CP60)
NASDAQ:CP60
CP60 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Market Leadership - CooperVisionLeading market share in contact lenses (about one-third of wearers) gives durable scale advantages: broader distribution, stronger negotiating power with suppliers and customers, recurring consumable revenue, and higher product-awareness barriers for competitors, supporting steady revenue and pricing resilience over time.
Business Diversification - CooperSurgicalGrowth in fertility, genomics and capital equipment diversifies revenue away from lenses, reducing cyclicality. High-growth, higher-value segments (capital equipment, consumables, genomics) create recurring service and consumable streams, improve margin mix potential, and provide multiple structural growth levers over the medium term.
Cash Generation & Balance SheetQuarterly FCF generation and lower net debt reflect improving cash conversion and leverage (debt-to-equity ~0.30). Strong cash flow capacity and a solid balance sheet support sustained investment in R&D, strategic M&A or capital returns, while providing flexibility to manage litigation payouts without structurally impairing operations.
Bears Say
Eroding ProfitabilityMaterial margin erosion year-over-year indicates weaker earnings quality and less cushion against cost shocks. Persistently lower net margins reduce return on equity and free cash flow conversion, limiting reinvestment capacity and making long-term EPS growth more dependent on volume gains or structural cost improvements.
Material Litigation Cash DemandsLarge, concentrated litigation accruals create near-term cash drains and GAAP volatility. Even if excluded from non‑GAAP metrics, settlement payouts can constrain capital allocation, slow buybacks or M&A, and introduce earnings uncertainty that can persist through 2026 while insurance recoveries and timing remain uncertain.
APAC Weakness & Inventory ActionsSustained APAC softness and legacy product rationalization can depress revenue in high-potential markets and lengthen recovery time. Inventory reductions and production slowdowns raise per-unit costs and, combined with FX/tariff headwinds, create structural margin pressure that may persist across multiple quarters into 2027.
Cooper Co News
CP60 FAQ
What was Cooper Companies’s price range in the past 12 months?
Currently, no data Available
What is Cooper Companies’s market cap?
Cooper Companies’s market cap is CHF10.47B.
When is Cooper Companies’s upcoming earnings report date?
Cooper Companies’s upcoming earnings report date is Sep 02, 2026 which is in 69 days.
How were Cooper Companies’s earnings last quarter?
Cooper Companies released its earnings results on Jun 04, 2026. The company reported $0.978 earnings per share for the quarter, beating the consensus estimate of $0.892 by $0.086.
Is Cooper Companies overvalued?
According to Wall Street analysts Cooper Companies’s price is currently Undervalued.
Does Cooper Companies pay dividends?
Cooper Companies does not currently pay dividends.
What is Cooper Companies’s EPS estimate?
Cooper Companies’s EPS estimate is 0.91.
How many shares outstanding does Cooper Companies have?
Currently, no data Available
What happened to Cooper Companies’s price movement after its last earnings report?
Cooper Companies reported an EPS of $0.978 in its last earnings report, beating expectations of $0.892. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cooper Companies?
Currently, no hedge funds are holding shares in CH:CP60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.84%
12-Months-Change
Fundamentals
Return on Equity
2.84%
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Company Description
Cooper Companies
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
CP60 Company Deck
CP60 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.View all CH:CP60 earnings summariesCP60 Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
CP60 Stock 12 Month Forecast
Average Price Target
$62.07
Options Prices
Currently, No data available
---